Additionally, the use of AAV-GALC gene therapy to prevent the development of these neuronal inclusions underscores the promise of this therapy to improve symptoms in not only KD patients but potentially a subset of patients affected by other synucleinopathies. This evidence concerns the gene GALC and synucleinopathy.